ConductScience.org, home

Paper42500932

A Multiple Enzyme-Mimetic Platinum-Ruthenium Nanohybrid Prodrug Potentiates Chemo-/Chemodynamic-/Immuno-Therapy of Hypoxic Tumors.

Yi H and 10 others. Adv Healthc Mater, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A Multiple Enzyme-Mimetic Platinum-Ruthenium Nanohybrid Prodrug Potentiates Chemo-/Chemodynamic-/Immuno-Therapy of Hypoxic Tumors. Papers, record 42500932. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42500932

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Multiple Enzyme-Mimetic Platinum-Ruthenium Nanohybrid Prodrug Potentiates Chemo-/Chemodynamic-/Immuno-Therapy of Hypoxic Tumors.
PubMed
Journal
Adv Healthc Mater
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-28
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yi HHuixi
2Zheng YYue
3Fu NNannan
4Li QQiuhua
5Xue SShanshan
6Zhan ZZhixiong
7Guo LLiyou
8Li JJingyao
9Yu XXiyong
10Shen JJianlianghttps://orcid.org/0000-0003-4351-4872
11Zhang DYDong-Yanghttps://orcid.org/0000-0003-3940-8911

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ProdrugsMajor topic
PlatinumMajor topic
RutheniumMajor topic
Antineoplastic AgentsMajor topic
ImmunotherapyMajor topic
NeoplasmsMajor topic
Animals
Humans
Cell Line, Tumor
Tumor Microenvironment
Mice
Mice, Inbred BALB C
Oxaliplatin
cGAS-STING Signaling Pathway
Nanoparticles

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
22207019National Natural Science Foundation of ChinaPubMed
2023HWYQ-073Natural Science Foundation of Shandong ProvincePubMed

Source PubMed

Download CSV of grants

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136134739A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.J Med Chem2022https://conductscience.org/library/papers/36134739PubMed
238227812Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance.ACS Nano2024https://conductscience.org/library/papers/38227812PubMed
331570880Tumour-intrinsic resistance to immune checkpoint blockade.Nat Rev Immunol2020https://conductscience.org/library/papers/31570880PubMed
415803154Tumour stem cells and drug resistance.Nat Rev Cancer2005https://conductscience.org/library/papers/15803154PubMed
528857075Chimeric antigen receptor T-cell therapies for lymphoma.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/28857075PubMed
640420701Metal Complexes Stimulating Immunogenic Pyroptosis as Burgeoning Antitumor Strategy.Angew Chem Int Ed Engl2025https://conductscience.org/library/papers/40420701PubMed
733045313Carrier-free nanodrugs for safe and effective cancer treatment.J Control Release2021https://conductscience.org/library/papers/33045313PubMed
831711497Role of hypoxia in cancer therapy by regulating the tumor microenvironment.Mol Cancer2019https://conductscience.org/library/papers/31711497PubMed
930299085Stimuli-Responsive Therapeutic Metallodrugs.Chem Rev2019https://conductscience.org/library/papers/30299085PubMed
1027610572A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.Cell2016https://conductscience.org/library/papers/27610572PubMed
1139285187Lattice expansion in ruthenium nanozymes improves catalytic activity and electro-responsiveness for boosting cancer therapy.Nat Commun2024https://conductscience.org/library/papers/39285187PubMed
1219930704The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer.J Exp Clin Cancer Res2009https://conductscience.org/library/papers/19930704PubMed
1335077133Rational Design of Nanotherapeutics Based on the Five Features Principle for Potent Elimination of Cancer Stem Cells.Acc Chem Res2022https://conductscience.org/library/papers/35077133PubMed
1426055486Hydrous RuO2 nanoparticles as an efficient NIR-light induced photothermal agent for ablation of cancer cells in vitro and in vivo.Nanoscale2015https://conductscience.org/library/papers/26055486PubMed
1539025943Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours.Nat Biomed Eng2024https://conductscience.org/library/papers/39025943PubMed
1635239514Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues.J Clin Invest2022https://conductscience.org/library/papers/35239514PubMed
1739744225Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer.Theranostics2025https://conductscience.org/library/papers/39744225PubMed
1838647488Free Radicals Generated in Perfluorocarbon-Water (Liquid-Liquid) Interfacial Contact Electrification and Their Application in Cancer Therapy.J Am Chem Soc2024https://conductscience.org/library/papers/38647488PubMed
1940035261Biotin Receptor-Targeting PtIV Oxygen Carrying Prodrug Amphiphile for Alleviating Tumor Hypoxia Induced Immune Chemotherapy Suppression.ACS Nano2025https://conductscience.org/library/papers/40035261PubMed
2033771859Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine.Sci Adv2021https://conductscience.org/library/papers/33771859PubMed

See all 54 referencesDownload CSV of references

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CAT847PubTator's text mininghttps://conductscience.org/library/genes/847NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CGAS115004PubTator's text mininghttps://conductscience.org/library/genes/115004NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene
STING1340061PubTator's text mininghttps://conductscience.org/library/genes/340061NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42500932

GET https://conductscience.org/api/papers/v1/42500932/references?page=2